Colossal Biosciences’ BioVault: A High-Tech Abdication of Conservation Policy?

When ‘Backup’ Becomes the Primary Strategy

A curious paradox is unfolding in American conservation. While the Trump administration actively dismantles the regulatory frameworks designed to protect endangered species, a US government agency is simultaneously partnering with a private biotechnology firm to bank their genetic material. The US Fish and Wildlife Service (USFWS) has announced a collaboration with Texas-based Colossal Biosciences to establish a national repository, dubbed the BioVault, for cryopreserving the DNA and tissues of over 2,300 imperiled plant and animal species. This initiative is being framed as a high-tech insurance policy, yet its very existence, at this specific political juncture, reveals a profound structural implication: we are opting for a technologically advanced, last-ditch effort over robust, proactive policy.

Colossal Biosciences, a five-year-old startup valued at more than $10 billion, has made headlines for its audacious de-extinction projects—from gene-editing gray wolves to resemble dire wolves, to ambitious plans for the woolly mammoth and dodo. Now, their BioVault project, which the company has reportedly invested “tens of millions of dollars” into, extends this genetic ambition to living endangered species. Colossal’s chief executive, Ben Lamm, insists the BioVault is merely a “redundancy backup” to traditional conservation. But a backup implies a primary system is in place and functioning. The actions of the current administration, however, suggest that system is being deliberately weakened.

The Illusion of Technological Solvency

Interior Secretary Doug Burgum praised the BioVault partnership as bringing together “scientific expertise” and the “ingenuity of the private sector.” He has previously, on platforms like X, cast the Endangered Species Act as favoring “regulation more than innovation”—a revealing statement that positions technological solutions as superior to, or even a replacement for, legislative protections. This sentiment explains why the administration, even as it convenes the rare “God Squad” to waive protections for offshore oil and gas drilling in the Gulf of Mexico, finds common ground with Colossal. According to Lamm, their pitch resonated because the administration “like[s] making money and saving money,” with Colossal fronting the costs for the biobank.

The underlying incentive for this timing is clear: the administration benefits from appearing to care about conservation through a private-sector, ‘innovation’-driven lens, without having to reverse its deregulation agenda. It offers a convenient narrative that bypasses the messy political work of habitat preservation, land acquisition, and enforcement. For Colossal, it legitimizes their futuristic ventures with a federal imprimatur, potentially opening doors to further government contracts and investment, as evidenced by the $60 million investment from the United Arab Emirates for a similar initiative.

However, this approach sidesteps a fundamental truth articulated by Noah Greenwald of the Center for Biological Diversity: “This isn’t biodiversity preservation. This is like a last-ditch effort. We’ll only need this genetic material if the administration fails at recovering endangered species.” His sharp observation cuts to the core of the problem: genetic banking, while a scientific marvel, does not address the root causes of species decline—habitat destruction, climate change, and human encroachment. It’s an exercise in preserving the raw ingredients while the kitchen burns down around them.

A Global Pattern of Reactive Fixes

While the USFWS points to the successful cloning of the black-footed ferret in 2021, using cryopreserved cells from the 1980s, as a precedent, such instances remain rare and resource-intensive. Cloning, or even de-extinction, requires not just genetic material but a viable ecosystem and host species—factors increasingly threatened by the very policies being enacted today. The idea that we can store genetic data, wait for a species to vanish, and then simply ‘reboot’ it later ignores the complexity of ecological systems and the irreplaceability of biodiversity in the wild.

This reliance on genetic libraries, while seemingly pragmatic, represents a broader trend I’ve observed globally: a preference for reactive, high-tech fixes over proactive, politically difficult policy changes. From climate engineering proposals emerging as nations fail to meet emissions targets, to smart cities designed to cope with congestion rather than addressing urban sprawl, the pattern repeats. We create sophisticated technological ‘redundancy backups’ for problems we are actively exacerbating through political inaction or deliberate policy choices. The Colossal BioVault is not, as Lamm suggests, merely a backup; it risks becoming a substitute, implicitly condoning the ongoing degradation of natural habitats by offering a future promise of technological salvation.

For intelligent, skeptical readers, the BioVault partnership is not just news; it is a signal. It signifies a future where the preservation of life itself might be outsourced to private companies armed with gene sequencers, while governments focus on extracting resources. The crucial question is not whether the technology works, but whether it allows us to avoid the harder, more impactful work of protecting species where they belong: in functioning ecosystems, not frozen vials in a lab in Dallas.